文献速递肺外科

早期肺癌胸腔镜与开胸肺叶切除的随机试验长期生存随访

Long-term survival from a randomized controlled trial of lobectomy by video-assisted thoracoscopic surgery versus thoracotomy for early-stage lung cancer.
PubMed 文献 · Eur J Cardiothorac Surg · 2025-01-01

该研究对2008至2014年纳入的206例疑似或确诊早期非小细胞肺癌患者进行随机分组,比较胸腔镜肺叶切除与开胸肺叶切除。中位随访12.8年后,两种术式的总生存、无病生存和癌症特异生存均无显著差异,但作者指出仍需更大样本的随机试验验证。

要点

  • 早期非小细胞肺癌胸腔镜与开胸肺叶切除的长期生存无显著差异
  • 中位随访12.8年时33%的患者仍存活
  • 该结论仍需更大样本随机试验进一步验证

核心结论

  • 胸腔镜与开胸肺叶切除在早期非小细胞肺癌的总生存、无病生存和癌症特异生存上无统计学显著差异。
  • 作者认为仍需更大样本、统计效能更高的随机试验来充分探索两种术式是否存在生存差异。

研究设计与样本

  • 2008至2014年随机对照试验的长期随访,206例疑似或确诊早期非小细胞肺癌患者随机分为胸腔镜组103例和开胸组103例。
  • 最终病理确诊非小细胞肺癌196例,失访4例,192例纳入随访分析。

主要发现

  • 总生存分析使用128个事件,无病生存分析使用100个事件,癌症特异生存分析使用79个事件。
  • 胸腔镜组99例、开胸组93例纳入分析,手术时中位年龄66岁(范围41-85岁)。
  • 中位随访12.8年(范围9.9-15.8年)后,33%的患者仍存活。
  • 总生存P=0.29,无病生存P=0.17,癌症特异生存P=0.31,两组间均无显著差异。

临床怎么用

  • 对于早期非小细胞肺癌,胸腔镜肺叶切除可作为与开胸手术生存结局相当的术式选择。
  • 长期随访结果支持胸腔镜作为早期肺癌首选术式的生存安全性。

局限性

  • 作者指出本试验样本量有限,生存分析统计效能不足。
  • 作者建议通过合并两个类似随机试验的生存数据进一步探索差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: We previously did a randomized clinical trial of lobectomy by video-assisted thoracoscopic surgery (VATS) or thoracotomy for early-stage lung cancer and found that patients who underwent VATS had less postoperative pain and better quality of life compared with thoracotomy. VATS has since been regarded the preferred surgical method for early-stage lung cancer. It is assumed that long-term survival is not influenced by surgical approach, but this assumption primarily rests on non-randomized comparative studies. We decided to do a long-term follow-up of patients who entered our previous randomized trial. METHODS: Between 2008 and 2014, we randomly assigned 206 patients to VATS (n = 103) or anterolateral thoracotomy (n = 103) for proven or suspected early-stage non-small-cell lung cancer (NSCLC). Records from patients with NSCLC on final pathology were identified in the national electronic patient-record system and the Danish Lung Cancer Registry. Overall, disease-free and cancer-specific survival (CSS) were estimated using the Kaplan-Meier method and log-rank test was used to compare the 2 interventions. RESULTS: A total of 196 patients had NSCLC on final histopathology. Four patients were lost to follow-up and the remaining 192 were included in this follow-up study with 128 events used for overall survival analysis, 100 events for disease-free survival analysis and 79 events for CSS analysis. VATS was used in 99 patients versus 93 by thoracotomy. Median age at time of surgery was 66 years (range 41-85 years). After a median follow-up time of 12.8 years (range 9.9-15.8 years), 33% of patients were alive. Overall, disease-free and CSS were not significantly different between VATS and thoracotomy: overall survival (P = 0.29), disease-free survival (P = 0.17) and CSS (P = 0.31). CONCLUSIONS: We did not find any statistically significant differences in overall, disease-free or CSS between VATS and thoracotomy. However, larger trials with better power for survival analysis are needed to fully explore if there are differences. Alternatively, differences in survival between thoracotomy and VATS for early-stage NSCLC could be investigated by pooling survival data from 2 similar randomized trials that have since been published.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Dittberner FA, Bendixen M, Licht PB, et al. Long-term survival from a randomized controlled trial of lobectomy by video-assisted thoracoscopic surgery versus thoracotomy for early-stage lung cancer. Eur J Cardiothorac Surg. 2025. PMID: 39873729. doi:10.1093/ejcts/ezaf017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。